The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Background Tocilizumab is a monoclonal antibody that interrupts interleukin-6 signalling,
reducing downstream effects on inflammation and the innate immune response. It was …

Despite evidence to support the safety and efficacy of COVID-19 vaccination in pregnancy,
and clear recommendations from professional organizations and the Centers for Disease …

Background Viral reactivations and co-infections have been reported among COVID-19
patients. However, studies on the clinical outcomes of different viral reactivations and co …

Background Preterm birth preceded by spontaneous preterm labour often occurs in the
clinical setting of sterile intra-amniotic inflammation (SIAI), a condition that currently lacks …

The clinical management of COVID-19 in pregnant women, who are considered a
vulnerable population, remains uncertain even as the pandemic subsides. SARS-CoV-2 …

Pregnant people have an elevated risk of severe COVID-19-related complications compared
to their non-pregnant counterparts, underscoring the need for safe and effective therapies. In …

The COVID-19 pandemic has been at the forefront of medicine over the last few years.
Pregnant women are often exposed to infectious agents that can be harmful not only to the …

Aim The objective of this study was to describe the use of COVID‐19‐related medicines
during pregnancy and their evolution between the early/late periods of the pandemic …

The COVID-19 pandemic posed a significant challenge for clinicians in managing pregnant
women, who were at high risk of virus transmission and severe illness. While the WHO …